This study showed the feasibility of enrolling asymptomatic ovarian cancer patients with CA-125 elevation in a trial with auranofin. One patient had a decline in CA-125, suggesting that PKCι inhibition merits further study in ovarian cancer.
nofin have been demonstrated to inhibit PKCι in vitro and have even shown promise in a recent phase I study -underscore the need to test the hypothesis that PKCι inhibition leads to antineoplastic effects in patients with ovarian cancer [1, 4] . Testing this hypothesis is particularly alluring in view of the fact that ovarian cancer is the most lethal gynecological malignancy and that, in the past 20 years, a limited number of drugs have been demonstrated to prolong overall survival in patients with this malignancy [5] .
In this context, we undertook a pilot trial to test auranofin in patients with epithelial ovarian cancer. Three aspects of our study design merit specific mention. First, because auranofin was to be administered as a single agent, we believe this gold compound was more likely to show proof of concept in the setting of a low tumor burden [1] . Consequently, this pilot trial targeted asymptomatic ovarian cancer patients with CA-125 elevation, as these patients were more likely to have a low tumor burden. Second, previous trials that had defined patient eligibility based on biochemical recurrence alone appeared slow to accrue [6] . Rustin et al. [7] went so far as to call CA-125 monitoring into question, demonstrating that such monitoring does not improve clinical outcomes and further calling into question whether this or future trials would ever be able to accrue with CA-125 elevation as part of the eligibility criteria. Launching a pilot study and assigning feasibility as the primary endpoint appeared appropriate. Finally, the growing controversy surrounding CA-125, as alluded to above, offered an opportunity to learn directly from patients how they view and understand the role of this tumor marker. For this reason, qualitative interviews were included in the study design.
For the reasons mentioned above, this 10-patient pilot trial focused on feasibility as its primary endpoint and incorporated a patient-centered qualitative methodology into the study design. Nonetheless, this trial served as an important platform from which to explore the antineoplastic effects of PKCι inhibition with auranofin in ovarian cancer patients. In essence, this pilot study was designed to lay the groundwork for future clinical trials that focus on PKCι inhibition in ovarian cancer patients.
Methods

Overview
This study was conducted at the Mayo Clinic in Rochester, Minn., USA. The Mayo Clinic's Institutional Review Board approved the study protocol, and all patients provided written informed consent prior to enrollment. This trial was listed on www. clinicaltrials.gov and was assigned the study No. NCT01747798.
Eligibility and Exclusion Criteria
To be eligible, patients had to meet the following criteria: (1) age ≥ 18 years; (2) histologic or cytologic evidence of epithelial ovarian, primary peritoneal, or fallopian tube cancer; (3) completion of initial cancer therapy, which potentially included surgery and/or postoperative chemotherapy; (4) Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0-2; (5) for patients with a first-time ovarian cancer recurrence, an increase in CA-125 defined as follows: normalization of CA-125 during firstline chemotherapy followed by an increase of ≥ 100 U/ml or a nadir of CA-125 beyond the upper limit of normal with a confirmatory measurement within 4 weeks or less of the same or a higher CA-125 value; (6) for patients who had received subsequent treatment for progressive cancer, CA-125 elevation beyond the institutional upper limit of normal; (7) the following laboratory values within 2 weeks of registration: absolute neutrophil count ≥ 1.5 × 10 9 cells/l, platelet count ≥ 100 × 10 9 cells/l, total bilirubin ≤ 1.5 times the institutional upper limit of normal, and creatinine within the institutional limit of normal; (8) for women of child-bearing potential, a negative pregnancy test within 1 week of registration, and (9) willingness to participate in a qualitative telephone interview about CA-125 monitoring.
Patients were excluded in the event of the following: (1) concurrent illness that, in the opinion of the treating oncologist, would make the patient inappropriate for study participation; (2) symptoms (other than anxiety, depression, and other psychological symptoms) that, in the opinion of the treating oncologist, were a direct result of cancer recurrence; (3) receiving other, medically prescribed, cancer treatment, or (4) being pregnant or nursing.
Pretreatment Assessment and Monitoring for Auranofin
All patients underwent an evaluation of their medical history, a physical examination, an assignment of their ECOG PS, and an adverse event assessment within 14 days of trial registration. Other testing performed within this time frame consisted of a hemogram, chemistry profile (total bilirubin, creatinine, and aspartate aminotransferase), CA-125, urinalysis, and, in the setting of documented measureable disease, radiographic imaging with the imaging modality left to the discretion of the treating health care provider.
Repeat medical history evaluations, physical examinations, weight measurements, adverse event assessments, and laboratory testing (including CA-125), as noted above, were undertaken on a monthly basis while the patients remained on auranofin. Every other month, the patients underwent testing for tumor measurements, as appropriate, and a urinalysis assessed proteinuria. RECIST criteria (version 1.1) were used to evaluate tumor response in the setting of measurable disease. Further monitoring after drug initiation included a weekly hemogram.
Qualitative Interviews
The patients participated in a 20-to 30-min semistructured interview designed to capture their understanding and impressions of CA-125 monitoring. These telephone interviews occurred shortly after study enrollment (interval not specified in the study protocol) and were audio recorded and transcribed. A trained female interviewer queried patients about the first time they had heard of CA-125, the positive and negative aspects of CA-125 monitoring, and the subjective value of this test for the patient and for others with ovarian cancer. Jatoi et al. 
210
Cancer Treatment Auranofin 3 mg twice a day (6 mg total dose per day) was prescribed orally on days 1-28 of a 28-day treatment cycle. This dose was derived from other indications [8] . Dose reductions were initiated based on adverse events; the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 4.0) were used to assess the latter. Grade 4 interim neutropenia or grade 3 or 4 thrombocytopenia was to prompt a 50% dose reduction at the time of starting the next treatment cycle. Similarly, grade 3 or worse skin toxicity, gastrointestinal toxicity, or other toxicity was to prompt a 50% dose reduction. If, at retreatment, patients manifested grade 2 or worse symptoms, auranofin was to be held until the symptoms abated to grade 1 or less in most circumstances. The exception was grade 2 proteinuria, which permitted restarting auranofin at the same dose. In the event toxicity did not lessen to an acceptable threshold after 2 weeks, the patient could no longer receive auranofin during the study.
Analyses
The primary purpose of this trial was to show that asymptomatic ovarian cancer patients with CA-125 elevation can be enrolled in a cancer-therapeutic trial within a reasonable time frame. We estimated an enrollment rate of 5 patients per year, with termination of the trial after 1 year if 3 or fewer patients were enrolled. A key secondary endpoint was to assess the rate of CA-125 stabilization. A 10-patient cohort provided 83% power to detect an improvement in the rate of CA-125 stabilization from 30 to 60% at 1 month after study enrollment, assuming a one-sided significance level of 0.20. Progression-free survival was defined as the time from registration to either cancer progression or death, whichever occurred first. Unless otherwise specified, all adverse event data are reported regardless of their attribution.
For the patient interview data, thematic analysis was used [9] . Two investigators (C.R.B. and A.J.) independently reviewed the interview transcripts and identified initial codes within the data. The initial codes were subsequently discussed, refined, and collated. Patterns, or themes, were identified with an inductive, datadriven approach that preserved internal homogeneity (similarity within a theme) and external homogeneity (distinction between themes) [10] .
Results
Demographics
Ten patients were recruited from March through October 2013. The patient characteristics are listed in table 1 , which shows the median age of the cohort to be 65 years (range: 54-81). Eight patients had an ECOG PS of 0, and 2 patients of 1. Four had baseline radiographic evidence of disease.
Auranofin Administration
For the 10 patients enrolled, the median treatment duration (range) was 2 (1-4) cycles. The reasons for stopping auranofin included cancer progression (n = 8 patients), nonspecific symptoms that started within only a few days of starting the agent (n = 1), and decline of further treatment per the patient (n = 1).
Tumor Response Parameters
Only 9 patients were evaluable for tumor response because 1 stopped therapy prior to the end of the first cycle. Four patients manifested stable disease, defined as neither a ≥ 50% increase in CA-125 (progression) nor a ≥ 50% drop in CA-125 (tumor response) within ≥ 1 month ( ≥ 1 cycle) of starting auranofin ( fig. 1 ). Values are numbers of patients unless indicated otherwise. The percent change in CA-125 levels from baseline is shown for all 9 evaluable patients. One patient manifested a notable and sustained drop in CA-125 of >50%. Each cycle length was 1 month.
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Of note, 1 patient had baseline and monthly CA-125 levels of 5,570, 6,085, 3,511, and 2,230 U/ml, respectively, over 3 months, only to stop therapy because of radiographic evidence of cancer progression. Her CA-125 increased to 7,168 U/ml approximately 3 months after stopping the auranofin treatment.
At the time of this report, only 1 patient had died. The median progression-free survival for the cohort was 2.8 months (95% CI: 1.3-3.8) ( fig. 2 ) . Of the 10 patients, 8 manifested progressive disease with either CA-125 elevation and/or new radiographic lesions, and 1 patient died without evidence of disease progression.
Adverse Events
Auranofin was well tolerated, and only grade 1 and 2 adverse events were reported. The most common included diarrhea (n = 5 patients), nausea (n = 5), and fatigue (n = 5), all of which were grade 1 in severity ( table 2 ) .
Qualitative Data on CA-125 Monitoring
Nine patients completed the qualitative interviews; 1 was not reachable by phone, despite multiple attempts. Three themes were identified from these interviews. The first was termed 'the role of CA-125 in cancer surveillance and monitoring'. This theme captured perceptions about the test itself as well as the utility and reassurance associated with monitoring CA-125 levels. Many patients appeared to be well informed about the CA-125 test, with a knowledge and understanding that seemed to have been gradually achieved. These patients favored its use as a surveillance tool but were also able to describe some of this test's limitations. The second theme was termed 'ardent advocacy of CA-125 testing'. This theme conveyed patients' desire to use the test not only for cancer surveillance but for ovarian cancer screening (for which it is not indicated). This theme captured patients' zeal for proactively recommending the test to others irrespective of cancer history, type or degree of cancer risk, and cost of testing. The final theme was termed 'evolution toward CA-125 assuming a life of its own'. This theme captured patients' description of what seemed to be an evolution in their own thinking about CA-125 elevation. This evolution spanned the emotionally charged nature of CA-125 elevation/decline, patients' grappling with a disconnect between CA-125 elevation and a lack of cancer symptoms, and an apparent 'shift' in therapeutic goals from a focus on the cancer to a focus on treating (lowering) CA-125. Indeed, patients cited their desire to receive cancer treatment primarily to bring down the CA-125 with little reference to treating the actual cancer. Representative quotes are shown in table 3 .
Discussion
This pilot trial succeeded in demonstrating that, despite shifting data on the value of CA-125 as a monitoring tool for cancer recurrence, asymptomatic ovarian cancer patients who require CA-125 elevation as part of a trial's eligibility criteria can be successfully identified and enrolled. In fact, we demonstrated an ability to exceed our target recruitment rate. Despite the landmark paper by Rustin et al. [7] and despite what appeared to be marginal accrual to other trials that relied on CA-125 in their eligibility criteria, our findings suggest that trials such as this one are still able to be completed in a timely manner [6, 7] . Cancer progression-free survival in our cohort of 10 patients. The median progression-free survival of the cohort was 2.8 months (95% CI: 1.3-3.8). More importantly, this study showed that PKCι inhibition with auranofin exhibits therapeutic value and merits further investigation. Four patients manifested stable disease with auranofin, albeit over a short interval. Remarkably, 1 patient manifested a notable drop in CA-125 which subsequently increased upon stopping auranofin. Although these data are too preliminary to allow for firm conclusions on therapeutic efficacy, they do suggest that further study of PKCι inhibition, either with auranofin alone or in combination with other therapeutic agents, is indicated. Importantly, auranofin was well tolerated and appeared to demonstrate antineoplastic effects even within a group of pretreated patients, thus providing additional justification for further study in ovarian cancer patients.
With respect to feasibility, this trial provided a wealth of information on how patients perceive CA-125 monitoring. As a result of the data from Rustin and others, we were concerned that patients would voice mixed feelings about CA-125 monitoring, as described by another group [11] prior to the publication of the paper by Rustin et al. [7] . Admittedly, CA-125 is associated with a roller coaster of emotions when it fluctuates, and by interviewing patients who had already enrolled in this auranofin trial, we likely captured the views of only patients who were perhaps more accepting of CA-125 monitoring in general. However, none of these 9 patients described any reluctance to undergo the test, and all appeared to value the availability of CA-125 monitoring -some even to the point of being ardent advocates. In the aggregate, these '… I was in absolute fear that it wasn't going down and that it wasn't going to normalize. And then when it did normalize, then my fear and anxiety were that it was going to go up … It always feels like the shoe is going to drop …' 'My husband is bringing me down from the ceiling every once in a while. It's usually just a matter of when I've got the number …' 'I don't feel any differently than I felt when my CA-125 was normal. It's just mentally that I know it is rising and it's made me, not fatalistic, but close to it.' '… and if it was down from the previous month, I was overjoyed thinking that "wow, we're going to kill all of this and be done with it." patients' comments provided further feasibility data to enable us to conclude that future studies that rely on CA-125 elevation to identify and recruit patients can be accomplished. However, it should be noted, that, in accordance with our last two themes, CA-125 monitoring is fraught with some misunderstanding (it is not a screening tool for ovarian cancer or for other cancers) and the CA-125 test is highly emotionally charged. These last two themes are important and should invite health care providers to further instruct patients on the CA-125 marker and its role in monitoring patients for recurrent or progressive ovarian cancer.
In summary, this trial shows that it is feasible to conduct studies that rely on CA-125 monitoring to identify and recruit patients. More importantly, the fact that 1 patient manifested a drop in CA-125 with auranofin suggests a role for studying auranofin either as a monotherapy or combined with other agents. Finally, this study shows a clear need to further educate patients on the role of CA-125 monitoring, to identify and correct patients' misunderstandings regarding this tumor marker, and to help patients cope with the emotionally charged nature of CA-125 fluctuations over time.
